Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies.

For Eli Lilly and Co LLY, ASCO will be all about single-agent data for Abemaciclib, which Schott sees as “clearly very active in breast cancer.” In addition, Schott is still awaiting combo data from MONARCH-2 and -3.

For Bristol-Myers Squibb Co BMY, Schott was impressed by the two-year survival data for Opdivo in 2L NSCLC. The updated data in the new abstract shows an overall two-year survival rate of 29 percent in non-sq and 23 percent in sq-NSCLC, higher than the respective 16 and 8 percent Docetaxel survival rates.

When it comes to Pfizer Inc. PFE, the highlight of ASCO will be the confirmatory phase III data for Ibrance. The abstract indicates that Pfizer has repeated the efficacy of its phase II PALOMA-1 study, achieving a mPFS of 24.8m, an ORR of 42.1 percent and CBR of 84.9 percent.

Finally, Merck & Co., Inc. MRK reported…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!